What are the ambitions in terms of expected results? How will these perspectives change the understanding or the way we manage metabolic diseases and diabetes in particular?
In the short term, we are focusing exclusively on launching the metabolome platform by the end of the year, while finalizing key publications. By combining our know-how on the metabolome and the microbiome, with that of EGID in human genetics and on preclinical models, I aim to create a differentiated theme, based on our ability to integrate the metabolome, the metagenome and the genome. of the host to better understand metabolic diseases.
These innovations will allow us to better understand the genetic and metagenomic determinants of human metabolism. This opens up therapeutic avenues for us, whether through broad-spectrum interventions acting on the microbiome such as intestinal microbiome transplants, supplementation with nutrients promoting the development of beneficial bacteria (prebiotics), and then treatments. more targeted based on new generation beneficial bacteria (probiotics), or on beneficial microbial compounds (postbiotics), but also through pharmacological targeting of certain microbial genes responsible for the production of deleterious metabolites. This is a whole repertoire of new therapeutic solutions.
As a first step, we will establish the technical platform and above all publish, to recognize EGID’s know-how, to obtain recognition from the supervisors, local, national and European actors. As research is not done in isolation, we keep very strong links with our international collaborators, whether in the United Kingdom, Europe or Canada. Thanks to the support of the University of Lille, we are precisely in the phase of launching an International Associated Laboratory with Imperial College in order to facilitate the exchange of know-how, the training of personnel from an analytical or chemo point of view. -informatics, and above all the establishment of a harmonized network of metabolomics centers for the study of human cohorts, the famous “Phenome Centers”.
Beyond metabolism, the microbiome and its compounds play a fundamental role in orchestrating human immunity, physiology and behavior. The Anglo-Saxon proverb says it well “the sky is the limit”, (note the limit, it is the sky)… And why not dream of going to reach the moon and to take our microscopic friends on other planets in the relatively near future?